Drug Overview
Phenytoin (brand name Dilantin) is a widely used anticonvulsant medication prescribed to prevent and control seizures in patients with epilepsy and related disorders.
It works by stabilizing neuronal membranes and reducing excitability through selective inhibition of voltage-gated sodium channels in the brain, thereby decreasing abnormal electrical activity that leads to seizures.
Because of its nonlinear pharmacokinetics and narrow therapeutic index, phenytoin dosing typically requires careful monitoring of blood levels to optimize treatment and minimize toxicity.
Relevant Genes and Their Roles
The pharmacogene Gene2Rx covers for phenytoin is CYP2C9, a liver enzyme responsible for metabolizing phenytoin into inactive compounds. Variants in CYP2C9 alter the enzyme's activity and directly affect drug clearance and blood levels.
Phenytoin also has a separate, well-known immune-mediated risk tied to HLA-B*15:02 (Stevens-Johnson syndrome and toxic epidermal necrolysis), particularly in patients of East Asian ancestry. Gene2Rx does not currently test HLA alleles. Patients of relevant ancestry starting phenytoin should ask their prescriber about HLA-B*15:02 testing through a clinical pharmacogenetics lab.
Impact of Genetics on Drug Response
Genetic differences in CYP2C9 define metabolizer phenotypes (poor, intermediate, normal) that directly influence phenytoin blood concentrations and therapeutic risk.
Want to know what your genetics say about how you'll respond to Phenytoin?
A Gene2Rx report reads your own DNA to show how it may affect your response to Phenytoin and your other medications.
{# data-track routes these through the sitewide cta_click listener in
base.html, which attaches page_type / drug_name / guide_slug from the
server-resolved page context. This one file instruments the mid-article
CTA on ~114 content pages. #}
Find out today
Or see an example report first
Expected Clinical Effects of Genetic Variation
Normal Metabolizer
- Effect on drug levels: Expected to metabolize phenytoin at typical rates, maintaining standard blood concentrations.
- Clinical consequence: Standard seizure control with usual dosing regimens.
- Side effects: Typical risk of dizziness or ataxia; severity and frequency align with general population rates.
Intermediate Metabolizer
- Effect on drug levels: Slower clearance leading to moderately increased blood concentrations.
- Clinical consequence: Slightly higher risk of dose-dependent toxicity; therapeutic levels should be monitored.
- Side effects: Mild to moderate central nervous system side effects (e.g., nystagmus, drowsiness); may occur somewhat more frequently.
Poor Metabolizer
- Effect on drug levels: Significantly reduced clearance causing substantially elevated blood concentrations.
- Clinical consequence: High risk of toxicity; dose reduction necessary to maintain safe levels.
- Side effects: Severe CNS toxicity such as ataxia and cognitive impairment; increased severity and frequency if unadjusted.
Indeterminate/Not Available
- Effect on drug levels: Unknown due to insufficient genetic information.
- Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring.
- Side effects: Uncertain; monitor for any signs of toxicity as per routine practice.
Dosing Guidelines
The following dosing guidelines are based on CPIC and FDA recommendations for CYP2C9.
CYP2C9 Dosing Guideline (CPIC)
| Phenotype |
Clinical Consequence |
Guideline Recommendation |
| Normal Metabolizer |
Normal phenytoin metabolism |
No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. |
| Intermediate Metabolizer (activity score 1.5) |
Slightly reduced metabolism without increased toxicity |
No adjustments needed from typical dosing strategies. Monitor response and side effects. |
| Intermediate Metabolizer (activity score 1.0) |
Reduced metabolism; higher probability of toxicity |
For first dose, use typical initial or loading dose. For subsequent doses, use ~25% less than typical maintenance dose and monitor closely. |
| Poor Metabolizer |
Significantly reduced metabolism with high toxicity risk |
For first dose, use typical initial or loading dose. For subsequent doses, use ~50% less than typical maintenance dose and adjust based on monitoring. |
| Indeterminate / Not available |
Unknown impact |
Initiate therapy with recommended starting dose and monitor clinically. |
A Note On Phenytoin Hypersensitivity
Phenytoin carries a separate, well-known immune-mediated risk that is not based on the CYP2C9 genetics covered in your Gene2Rx report. The HLA-B*15:02 allele is strongly associated with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, particularly in patients of East Asian ancestry. Gene2Rx does not currently test HLA alleles. If your ancestry includes populations where HLA-B*15:02 is common, ask your prescriber whether HLA-B*15:02 testing is appropriate before starting phenytoin; that testing is offered separately by clinical pharmacogenetic laboratories.
Genes that affect Phenytoin
See the full list of drugs affected by each gene:
Brand names containing Phenytoin
See how your genetics affect each product Phenytoin shows up in:
Related Guides
Learn more about how genetics may affect your response to Phenytoin and related medications:
Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.
Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.
I'm Interested